Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; maize starch; colloidal anhydrous silica; carbomer 941 - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet - excipient ingredients: hyprolose; sodium citrate; crospovidone; magnesium stearate; mannitol; pregelatinised maize starch; colloidal anhydrous silica - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet - excipient ingredients: crospovidone; colloidal anhydrous silica; mannitol; sodium citrate; pregelatinised maize starch; hyprolose; magnesium stearate - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: hyprolose; colloidal anhydrous silica; crospovidone; magnesium stearate; pregelatinised maize starch; sodium citrate; mannitol - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - isosorbide mononitrate, quantity: 60 mg - tablet, modified release - excipient ingredients: purified talc; titanium dioxide; lactose monohydrate; hypromellose; stearic acid; magnesium stearate; iron oxide yellow; macrogol 4000; carnauba wax; colloidal anhydrous silica - prophylactic treatment of angina pectoris. apo- isosorbide mononitrate 60mg sustained release tablets are not recommended for the management of acute attacks of angina pectoris (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 90.6 mg (equivalent: ziprasidone, qty 80 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; gelatin; pregelatinised maize starch; lactose monohydrate; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 67.95 mg (equivalent: ziprasidone, qty 60 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; lactose monohydrate; titanium dioxide; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 45.3 mg (equivalent: ziprasidone, qty 40 mg) - capsule, hard - excipient ingredients: magnesium stearate; indigo carmine; titanium dioxide; lactose monohydrate; pregelatinised maize starch; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 22.65 mg (equivalent: ziprasidone, qty 20 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; indigo carmine; gelatin; lactose monohydrate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ethinylestradiol 30ug; levonorgestrel 150ug; ethinylestradiol 30ug; levonorgestrel 150ug - tablet - 30mcg/150mcg - active: ethinylestradiol 30ug levonorgestrel 150ug excipient: calcium carbonate glycerol glycol/butylene glycol montanate iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate povidone   purified talc   purified water starch sucrose titanium dioxide calcium carbonate erythrosine montangylycol wax (wax e pharma) (dab) lactose monohydrate macrogol 6000 magnesium stearate ponceau 4r povidone   purified talc   starch sucrose active: ethinylestradiol 30ug levonorgestrel 150ug excipient: calcium carbonate carnauba wax white wax, polishing lactose monohydrate macrogol 6000 magnesium stearate povidone   purified talc   purified water starch sucrose calcium carbonate erythrosine montangylycol wax (wax e pharma) (dab) macrogol 6000 magnesium stearate ponceau 4r povidone purified talc starlac sucrose calcium carbonate erythrosine wax e pharma lactose macrogol 6000 magnesium stearate maize starch ponceau 4r povidone   purified talc   purified water sucrose - monofeme is indicated for prevention of pregnancy.